Sodium fluoride-18 and radium-223 dichloride uptake colocalize in osteoblastic mouse xenograft tumors. Phelps TE, Roy J, Green MV, Seidel J, Baidoo KE, Adler S, et al. Preclinical single photon emission computed tomography of alpha particle-emitting radium-223. 2019 44:401–3.Ībou DS, Rittenbach A, Tomlinson RE, Finley PA, Tsui B, Simons BW, et al. 225Ac Prostate-specific membrane antigen posttherapy alpha imaging: comparing 2 and 3 photopeaks. Usmani S, Rasheed R, Al Kandari F, Marafi F, Naqvi SAR. Feasibility of thorium-227/radium-223 gamma-camera imaging during radionuclide therapy. Larsson E, Brolin G, Cleton A, Ohlsson T, Linden O, Hindorf C. 203/212Pb theranostic radiopharmaceuticals for image-guided radionuclide therapy for cancer. Li M, Sagastume EA, Lee D, McAlister D, DeGraffenreid AJ, Olewine KR, et al. Sensitization of tumor to 212Pb radioimmunotherapy by gemcitabine involves initial abrogation of G2 arrest and blocked DNA damage repair by interference with Rad51. Yong KJ, Milenic DE, Baidoo KE, Brechbiel MW. 212Pb-radioimmunotherapy induces G(2) cell-cycle arrest and delays DNA damage repair in tumor xenografts in a model for disseminated intraperitoneal disease. Radiobiological effects of the alpha emitter Ra-223 on tumor cells. 2012 751:158–246.īannik K, Madas B, Jarzombek M, Sutter A, Siemeister G, Mumberg D, et al. Recognition, signaling, and repair of DNA double-strand breaks produced by ionizing radiation in mammalian cells: the molecular choreography. Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant prostate cancer patients. Yadav MP, Ballal S, Sahoo RK, Tripathi M, Seth A, Bal C. 225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer. Kratochwil C, Bruchertseifer F, Giesel FL, Weis M, Verburg FA, Mottaghy F, et al. Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety. Cellular and genetic determinants of the sensitivity of cancer to alpha-particle irradiation. Yard BD, Gopal P, Bannik K, Siemeister G, Hagemann UB, Abazeed ME. Mechanisms of resistance to high and low linear energy transfer radiation in myeloid leukemia cells. Global comparison of targeted alpha vs targeted beta therapy for cancer: in vitro, in vivo and clinical trials. Sublethal exposure to alpha radiation ( 223Ra dichloride) enhances various carcinomas’ sensitivity to lysis by antigen-specific cytotoxic T lymphocytes through calreticulin-mediated immunogenic modulation. Malamas AS, Gameiro SR, Knudson KM, Hodge JW. Basic mechanisms of therapeutic resistance to radiation and chemotherapy in lung cancer. Willers H, Azzoli CG, Santivasi WL, Xia F. Clustered damages and total lesions induced in DNA by ionizing radiation: oxidized bases and strand breaks. Sutherland BM, Bennett PV, Sidorkina O, Laval J. Initial events in the cellular effects of ionizing radiations: clustered damage in DNA. Molecular pathways: targeted alpha-particle radiation therapy. 2019 4:27.īaidoo KE, Yong K, Brechbiel MW. Auger electrons for cancer therapy - a review. Survival and DNA damage in Chinese hamster V79 cells exposed to alpha particles emitted by DNA-incorporated astatine-211. Walicka MA, Vaidyanathan G, Zalutsky MR, Adelstein SJ, Kassis AI. Advances in radiotherapy and implications for the next century: a historical perspective. Biological response of cancer cells to radiation treatment. Radiopharmaceutical therapy in cancer: clinical advances and challenges. Sgouros G, Bodei L, McDevitt MR, Nedrow JR. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fossa SD, et al. Efficacy and safety of high-specific-activity 131I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma. Pryma DA, Chin BB, Noto RB, Dillon JS, Perkins S, Solnes L, et al.
#Alpha particle trial
Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al.
0 kommentar(er)
